A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects with Selected Advanced Solid Tumors
Evaluating the safety and effectiveness of study drug AMG 228 in patients with Advanced Solid Tumors
Sponsor: Amgen
Enrolling: Male and Female Patients
IRB Number: AAAO9909
U.S. Govt. ID: NCT02437916
Contact: Victoria Vulaj: 212-305-0455 / vv2218@columbia.edu
Additional Study Information: This study is for patients with the following cancers: advanced non-small cell lung cancer, head and neck cancer, melanoma, colon cancer, or bladder cancer. The purpose of this study is to find out more about the effects of AMG 228 in people and on their cancer. AMG 228 is an experimental drug that is being developed to stimulate the bodys immune system to kill cancer cells. This study is the first totest AMG 228 in people. This study will look at what doses of AMG 228 are safe for people totake and whether it causes any side effects. The first group of patients will receive a lower dose and then, if the drug is well tolerated, additional groups of patients will receive the medicine at a higher dose.
This study is closed
Investigator
Yvonne Saenger, MD
Do You Qualify?
Have you been diagnosed with an advanced solid tumor? Yes No
Do you have an active autoimmune disease/ history of autoimmune disease Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Victoria Vulaj
vv2218@columbia.edu
212-305-0455